Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Expert Opin Ther Pat
; 31(4): 309-324, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-947613
ABSTRACT
INTRODUCTION:
The two cysteine proteases from the coronaviruses, which produced deadly outbreaks in the last two decades, SARS CoV-1/2, and MERS, the main protease (Mpro) and the papain-like protease (PLP) are conserved among the three pathogens and started to be considered as exciting drug targets for developing antivirals. AREAS COVERED We review the drug design landscape in the scientific and patent literature to design peptidomimetic and non-peptidomimetic protease inhibitors (PIs) targeting these proteins. EXPERT OPINION The X-ray crystal structures of some of these proteases, alone and in complex with various inhibitors, were crucial for the discovery of effective such compounds, some of which also showed considerable antiviral activity and are considered preclinical candidates to fight these emerging infections, which in the case of Covid-19 already provoked an unprecedented worldwide pandemic.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Protease Inhibitors
/
Coronavirus 3C Proteases
/
Coronavirus Papain-Like Proteases
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Expert Opin Ther Pat
Journal subject:
Therapeutics
Year:
2021
Document Type:
Article
Affiliation country:
13543776.2021.1857726
Similar
MEDLINE
...
LILACS
LIS